Loading...
NovAliX enters into fragment-based drug discovery alliance with Kyowa Hakko Kirin
17-Jan-2013
- France
Advertisement
NovAliX SAS announced that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan.
Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets.
Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.